Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 232 (ZNF232) is a predicted DNA-binding transcription factor and member of the SCAN domain subfamily of C2H2-type zinc finger proteins, encoded by a gene located on chromosome 17p12[1][2][3][4][5]. It contains a SCAN domain, enabling protein-protein interactions, and five C2H2 zinc fingers, which mediate sequence-specific DNA binding[1][5]. ZNF232 is suggested to localize to the nucleus and is expressed in a wide range of human tissues, with possible tissue-specific regulation through alternative splicing[1][2][3]. Its probable function is the regulation of gene transcription by RNA polymerase II, though its specific physiological or therapeutic roles are not well-defined and there are no known drugs targeting this protein[2][3]. Diseases associated with ZNF232 include kidney rhabdoid cancer and congenital myopathy 4A, but its precise contribution is not established[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 232 (ZNF232).